Medtronic Announces Two Worldwide Clinical Trials To Study Medical Device Interventions For Stroke
Each year, approximately 795,000 people experience a new or recurrent stroke1 in the United States, and approximately a half million people in Western Europe are similarly afflicted2. Today, Medtronic, Inc. (NYSE: MDT) announces two significant clinical trials related to medical device interventions for stroke. First enrollments in the global CRYSTAL AF (Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke) trial have taken place.
More: continued here
Filed under: Clinical Trials on June 27th, 2009
You must be logged in to post a comment.